Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the sector include Amgen ( AMGN), up 1.1%, AstraZeneca ( AZN), up 1.0%, Gilead ( GILD), up 0.9%, Medtronic ( MDT), up 0.9% and Eli Lilly and ( LLY), up 0.8%. On the negative front, top decliners within the sector include Alere ( ALR), down 13.5%, Catamaran ( CTRX), down 3.1%, Taro Pharmaceutical Industries ( TARO), down 2.7%, ResMed ( RMD), down 1.9% and Teva Pharmaceutical Industries ( TEVA), down 1.7%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. NPS Pharmaceuticals ( NPSP) is one of the companies pushing the Health Care sector higher today. As of noon trading, NPS Pharmaceuticals is up $1.54 (5.5%) to $29.40 on average volume. Thus far, 943,386 shares of NPS Pharmaceuticals exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $27.66-$29.59 after having opened the day at $28.18 as compared to the previous trading day's close of $27.86. NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS Pharmaceuticals has a market cap of $3.0 billion and is part of the drugs industry. Shares are down 8.2% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates NPS Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full NPS Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.